Federated Hermes
EGRX

Federated Hermes’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Federated Hermes’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,830
Closed -$9.59K – 2159
2024
Q1 		$9.59K Buy
1,830
+642
+54% +$3.52K ﹤0.01% 1779
2023
Q4 		$6.21K Buy
+1,188
New +$11.7K ﹤0.01% 1833
2023
Q3 		– Sell
-35,240
Closed -$685K – 2227
2023
Q2 		$685K Sell
35,240
-31,839
-47% -$755K ﹤0.01% 1263
2023
Q1 		$1.9M Sell
67,079
-3,032
-4% -$90K ﹤0.01% 974
2022
Q4 		$2.05M Sell
70,111
-31,523
-31% -$1M 0.01% 902
2022
Q3 		$2.69M Sell
101,634
-29,706
-23% -$1.09M 0.01% 830
2022
Q2 		$5.83M Sell
131,340
-73
-0.1% -$3.35K 0.02% 657
2022
Q1 		$6.5M Buy
131,413
+2,526
+2% +$121K 0.01% 717
2021
Q4 		$6.56M Buy
128,887
+185
+0.1% +$9.59K 0.01% 750
2021
Q3 		$7.18M Buy
128,702
+6,112
+5% +$301K 0.01% 736
2021
Q2 		$5.25M Sell
122,590
-4,259
-3% -$176K 0.01% 822
2021
Q1 		$5.29M Buy
126,849
+37,052
+41% +$1.72M 0.01% 838
2020
Q4 		$4.18M Buy
89,797
+34,426
+62% +$1.61M 0.01% 855
2020
Q3 		$2.35M Buy
+55,371
New +$2.42M 0.01% 930
2020
Q1 		– Sell
-7,932
Closed -$477K – 2378
2019
Q4 		$477K Sell
7,932
-29,118
-79% -$1.74M ﹤0.01% 1461
2019
Q3 		$2.1M Sell
37,050
-61,305
-62% -$3.45M 0.01% 1019
2019
Q2 		$5.48M Sell
98,355
-43,536
-31% -$2.27M 0.01% 756
2019
Q1 		$7.16M Buy
141,891
+108,649
+327% +$4.83M 0.02% 678
2018
Q4 		$1.34M Buy
+33,242
New +$1.71M ﹤0.01% 1189
2018
Q2 		– Sell
-8,723
Closed -$460K – 2285
2018
Q1 		$460K Buy
+8,723
New +$507K ﹤0.01% 1408
2016
Q1 		– Sell
-4,651
Closed -$412K – 2186
2015
Q4 		$412K Sell
4,651
-3,405
-42% -$269K ﹤0.01% 1341
2015
Q3 		$596K Buy
8,056
+8,042
+57,443% +$669K ﹤0.01% 1234
2015
Q2 		$1K Buy
+14
New +$912 ﹤0.01% 1918

Other funds holding EGRX

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Federated Hermes's EGRX Position: Q2 2024 in Review

Federated Hermes sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2024, closing a stake of 1,830 shares — an estimated $9.59K sold.

Federated Hermes first reported a position in EGRX in Q2 2015 and held it in 23 quarters. The position peaked at $7.18M in Q3 2021. 75 funds tracked by Wall St. Rank hold EGRX as of Q2 2024.

  • Federated Hermes reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
  • Federated Hermes sold 1,830 Eagle Pharmaceuticals, Inc. shares in Q2 2024, an estimated $9.59K.
  • Federated Hermes first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2015 and held it in 23 quarters.
  • Federated Hermes's Eagle Pharmaceuticals, Inc. position peaked at $7.18M in Q3 2021.
  • 75 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2024.

Based on Federated Hermes's 13F filing for Q2 2024, filed 8 Aug 2024.